MediWound Ltd. (MDWD) Given a $10.00 Price Target by Oppenheimer Holdings, Inc. Analysts
MediWound Ltd. (NASDAQ:MDWD) received a $10.00 target price from Oppenheimer Holdings, Inc. in a research note issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 98.02% from the company’s current price.
A number of other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Jefferies Group LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of MediWound in a report on Thursday, September 28th. ValuEngine lowered shares of MediWound from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. Cowen and Company assumed coverage on shares of MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a report on Monday, June 26th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $9.15.
Shares of MediWound (NASDAQ MDWD) traded down 0.79% during midday trading on Tuesday, hitting $5.01. 4,867 shares of the stock traded hands. MediWound has a 52 week low of $4.25 and a 52 week high of $8.25. The company’s market capitalization is $109.99 million. The firm’s 50-day moving average is $5.44 and its 200 day moving average is $6.34.
MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The firm’s revenue was up 93.8% compared to the same quarter last year. During the same period last year, the company posted ($0.34) EPS. Equities analysts forecast that MediWound will post ($0.76) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “MediWound Ltd. (MDWD) Given a $10.00 Price Target by Oppenheimer Holdings, Inc. Analysts” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/19/mediwound-ltd-mdwd-given-a-10-00-price-target-by-oppenheimer-holdings-inc-analysts.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. raised its holdings in MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares during the last quarter. Wells Fargo & Company MN raised its holdings in MediWound by 23.5% in the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares during the last quarter. Renaissance Technologies LLC raised its holdings in MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in MediWound by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares during the last quarter. Institutional investors and hedge funds own 19.55% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.